Information  X 
Enter a valid email address

Incanthera PLC (INC)

  Print      Mail a friend

Monday 19 April, 2021

Incanthera PLC

Directors Dealings

RNS Number : 8072V
Incanthera PLC
19 April 2021
 

 

 

19 April 2021

 

Incanthera plc

 

("Incanthera" or the "Company")

 

Directors dealings

 

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology announces the purchase of shares in the Company by Directors of the Board and Senior Management Team (the "Transactions").

 

The Transactions, recorded on 15 April 2021, on AQSE Growth Market, are as follows:

 

Employee  Company Position  Transaction Volume  Purchase Price 

Tim McCarthy                    Chairman                                              49,382  13.50p 

Simon Ward  CEO  51,593                                   13.50p

Pawel Zolnierzyck             COO                                                        11,307                                   13.20p

Laura Brogden  CFO  15,057                                    13.15p

Suzanne Brocks Head of Communications                   50,000  13.00p

   

 

Total Shareholdings following the Transactions:

 

Employee  Company Position  Total Shareholding  % of Share Capital

Tim McCarthy  Chairman                                              3,931,646  5.31%

Simon Ward                       CEO  2,704,199  3.65% 

Pawel Zolnierzyck             COO                                                        669,544                              0.90% 

Laura Brogden  CFO                                                         46,034     0.06% 

Suzanne Brocks Head of Communications                   325,594                                0.44%                         

   

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic   UK   law pursuant to the European Union (Withdrawal) Act 2018).

 

 

For further enquiries:

 

Incanthera plc

www.incanthera.com

 

Tim McCarthy, Chairman

[email protected]

 

Simon Ward, Chief Executive Officer

[email protected]

 

Suzanne Brocks, Head of Communications

[email protected]

 

 

 

+44 (0) 7831 675747

 

 

+44 (0) 7747 625506

 

 

+44 (0) 7776 234600

 

 

Aquis Exchange Corporate Adviser:

Cairn Financial Advisers LLP

Jo Turner/James Lewis/Mark Rogers

+44 (0) 20 7213 0880

 

 

Broker:

Stanford Capital Partners Ltd

Patrick Claridge/Tom Price/John Howes/Bob Pountney

+44 (0) 20 3815 8880

 

 

Notes to Editors

 

Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

 

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.

 

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

 

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

 

For more information on the Company please visit: www.incanthera.com


 

Notification and public disclosure of transactions by persons discharging managerial responsibilities/ person closely associated with them.

 

1.

Details of the person discharging managerial responsibilities/person closely associated

 

 Name

 

 

1.  Tim McCarthy

Chairman

2.  Simon Ward

CEO

3.  Pawel Zolnierczyk 

PDMR

4.  Laura Brogden 

PDMR

5.  Suzanne Brocks 

PDMR

 

2.

Reason for the notification

a)

Position/status

As above

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Incanthera plc

b)

LEI

2138002HEV4UFBOEXQ97

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares of 0.02p

b)

Identification code

GB00BGL7YW15

c)

Nature of the transactions

Purchase of Ordinary Shares

d)

Volumes and Prices

 

Volume

Price

1.  49,382

13.50p

2.  51,593

13.50p

3.  11,307

13.20p

4.  15,057

13.15p

5.  50,000

13.00p

 

e)

Aggregated information

-   Aggregated volume

-   Price

 

Volume

Prices

  177,339

 

  13.00-13.50p

 

f)

Date of the transactions

15  April 2021

f)

Place of the transactions

AQSE Growth Market, UK

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXDKFBPFBKDFQD

a d v e r t i s e m e n t